ReviewHealth science reports2026
Insights From Quantitative Susceptibility Mapping: An Umbrella Review of Multiple Sclerosis.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Insights From Quantitative Susceptibility Mapping: An Umbrella Review of Multiple Sclerosis.Health science reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and neurodegeneration. Conventional MRI techniques lack specificity for detecting subtle pathological changes, such as iron deposition and myelin dynamics. Quantitative susceptibility mapping (QSM), an advanced MRI method sensitive to tissue magnetic susceptibility (χ), has emerged as a promising tool for evaluating iron-related pathology and demyelination in MS. This umbrella review synthesizes evidence from systematic reviews and meta-analyses to consolidate the role of QSM in MS diagnosis, monitoring, and prognostication. Methods: Following PRISMA guidelines, a comprehensive search of PubMed, Scopus, Web of Science, and Embase identified seven studies (four meta-analyses, three systematic reviews) encompassing 5389 MS patients, covering publications up to January 1, 2025. Methodological quality was assessed using AMSTAR 2, revealing moderate-to-low confidence in findings. Results: Key results demonstrated elevated χ in deep gray matter structures-particularly the globus pallidus, putamen, and caudate nucleus-in MS patients compared to healthy controls, correlating with clinical disability (e.g., Expanded Disability Status Scale scores) and cognitive dysfunction. Thalamic χ exhibited dynamic patterns, with reduced susceptibility in advanced disease stages. QSM outperformed conventional techniques (e.g., R2*, SWI) in detecting iron deposition, differentiating lesion types (e.g., paramagnetic rim lesions), and distinguishing MS from mimics. Rim-enhancing lesions showed higher χ values linked to inflammatory activity, while white matter lesions reflected demyelination-driven susceptibility changes. Despite QSM's diagnostic and prognostic potential, methodological heterogeneity and inconsistent standardization of PRL criteria limit comparability. Conclusion: This review underscores QSM's utility as a biomarker for MS pathophysiology while advocating for standardized protocols and longitudinal studies to validate its clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.